Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study
SourceClinical Infectious Diseases, 71, 10, (2020), pp. e714-717
Article / Letter to editor
Display more detailsDisplay less details
Clinical Infectious Diseases
SubjectRadboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences
This phase-IV study investigated the influence of pregnancy on the pharmacokinetics of elvitegravir/cobicistat in 14 HIV-1-positive women. The results support the recommendation against elvitegravir/cobicistat use during pregnancy, as the elvitegravir Ctrough was reduced by 77%, with 85% of pregnant women having a Ctrough below the EC90.
Upload full text